Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026
Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Company Deals

Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam

Fineline Cube Jan 27, 2026
Company Deals

Insilico Medicine Partners with Qilu Pharma on AI Drug Development

Fineline Cube Jan 27, 2026
Company Deals

Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader

Fineline Cube Jan 27, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Fineline Cube Jan 28, 2026
Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Fineline Cube Jan 28, 2026
Company Medical Device

Venus Medtech Initiates Global Study with Venus Vitae TAVR System Implantations

Fineline Cube Sep 6, 2024

Venus Medtech (Hangzhou) Inc., listed on the Hong Kong Stock Exchange as HKG: 2500, has...

Policy / Regulatory

China’s Hainan Free Trade Port Implements ‘Zero Tax’ on Medical Imports for Designated Entities

Fineline Cube Sep 6, 2024

In a joint effort to bolster healthcare services, China’s Ministry of Finance, National Health Commission...

Company Drug

Viatris Launches First-of-Its-Kind Nasal Spray Dymista in China for Allergic Rhinitis

Fineline Cube Sep 6, 2024

Viatris Inc. (NASDAQ: VTRS), a leading global pharmaceutical company based in the U.S., has announced...

Company Medical Device

Sansure Biotech Wins NMPA Nod for ALDH2 Gene Polymorphism Detection Kit

Fineline Cube Sep 5, 2024

Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...

Company Drug

Novo Nordisk Advances in China with Submission of Sogroya for Adult Growth Hormone Deficiency

Fineline Cube Sep 5, 2024

Denmark’s pharmaceutical heavyweight, Novo Nordisk (NYSE: NVO), has reached a significant milestone with the National...

Company

AstraZeneca China Restructures Biopharma Unit to Boost Chronic Disease Management

Fineline Cube Sep 5, 2024

AstraZeneca (NASDAQ: AZN)’s Chinese subsidiary has announced a strategic restructuring of its China biopharmaceutical business...

Company Drug

Kelun-Biotech’s ADC for Cancer Gets NMPA Review, Expands MSD Collaboration

Fineline Cube Sep 5, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has achieved a regulatory milestone with its clinical...

Company Deals R&D

Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments

Fineline Cube Sep 5, 2024

Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked...

Company Drug

Roche’s Columvi for Relapsed DLBCL Gets Review Nod from China’s CDE for New Indication

Fineline Cube Sep 5, 2024

The Center for Drug Evaluation (CDE) in China has accepted for review an additional indication...

Company Drug

Jiangsu Hengrui’s Ivarmacitinib for Adult Alopecia Areata Accepted for Review by China’s CDE

Fineline Cube Sep 5, 2024

The Center for Drug Evaluation (CDE) has given the green light for the review of...

Policy / Regulatory R&D

US Allows Science and Technology Agreement with China to Expire, Pointing to Deepening R&D Competition

Fineline Cube Sep 5, 2024

The US-China Science and Technology Agreement (STA), a pivotal accord initially inked in 1979 by...

Company

Novartis Builds Two Radioligand Therapy Facilities in U.S. to Expand Cancer Treatment Capabilities

Fineline Cube Sep 5, 2024

Novartis AG (NYSE: NVS), a Swiss pharmaceutical giant listed on the NYSE under the ticker...

Deals

Jiangsu Suzhou Launches $843 Million Biomedicine Fund to Boost Pharma and Medical Device Innovation

Fineline Cube Sep 5, 2024

The Jiangsu Suzhou Biomedicine Industry Special Fund of Fund (FoF), a colossal pharmaceutical investment vehicle...

Company Deals

Sage Group Expands into China’s Healthcare Market with Cenponts Healthcare Partnership

Fineline Cube Sep 5, 2024

Sage Group, a UK-based financial advisory powerhouse, has announced a strategic foray into China’s burgeoning...

Company Drug

Hanx Biopharmaceuticals Receives NMPA Approval for HX009 Combination Therapy Phase II Trial

Fineline Cube Sep 5, 2024

On September 5, 2024, China-based Hanx Biopharmaceuticals Co., Ltd announced that it has received approval...

Company Deals

E-commerce and Physical Stores to Stock Hanmi’s OTC Drugs Following Shanghai Pharma Deal

Fineline Cube Sep 4, 2024

Hanmi Pharmaceutical, a leading South Korean pharmaceutical company, has reportedly entered into a supply agreement...

Company

Aspen Pharmacare’s 2024 Fiscal Report Shows Mixed Results Amid China’s VBP Impact

Fineline Cube Sep 4, 2024

Aspen Pharmacare Holdings Ltd (JSE: APN), a leading South African pharmaceutical company, has reported its...

Company Drug

European Commission Approves Merck’s Keytruda-Padcev Combo for First-Line Urothelial Carcinoma Treatment

Fineline Cube Sep 4, 2024

Merck & Co., Inc. (NYSE: MRK), a global healthcare leader based in the United States,...

Company Drug

Manufacturing Challenges for Novo Nordisk’s Ozempic Impact Diabetes and Obesity Treatments in Europe

Fineline Cube Sep 4, 2024

Novo Nordisk (NYSE: NVO), a leading Danish pharmaceutical company, has released a joint statement with...

Company Drug

Skyline Therapeutics’ Gene Therapy Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment

Fineline Cube Sep 4, 2024

Skyline Therapeutics, a biopharmaceutical company based in China, has received Orphan Drug Designation (ODD) from...

Posts pagination

1 … 251 252 253 … 615

Recent updates

  • Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial
  • J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen
  • Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial
  • FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link
  • Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Company Drug

Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial

Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.